Kevin Judice plays DiCE, pivoting from a $60M raise straight to the big S-1 filing

These days, it’s not hard to tell when a biotech is getting ready to launch an IPO.

Earlier this week, Kevin Judice tipped his hand when DiCE Molecules put out a terse release about raising $60 million. An enthusiastic advocate of his work on an oral IL-17 drug to...

Click to view original post